Efficacy and safety of teneligliptin added to glimepiride in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled study with an open-label, long-term extension-Reference-Cited by-同舟云学术

Efficacy and safety of teneligliptin added to glimepiride in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled study with an open-label, long-term extension

Published:2013-12-10 Issue:5 Volume:16 Page:418-425
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Kadowaki T.¹,Kondo K.²

Affiliation:

1. Department of Metabolic Diseases, Graduate School of Medicine; The University of Tokyo; Tokyo Japan

2. Development Division; Mitsubishi Tanabe Pharma Corporation; Tokyo Japan

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/dom.12235/fullpdf

Reference18 articles.

1. Glucagon-like peptide-1 7-36: a physiological incretin in man;Kreymann;Lancet,1987

2. Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39;Edwards;Diabetes,1999

3. Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects;Deacon;Diabetes,1995

4. Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes;Holst;Diabetes,1998

5. Effects of once-daily teneligliptin on 24-h blood glucose control and safety in Japanese patients with type 2 diabetes mellitus: a 4-week, randomized, double-blind, placebo-controlled trial;Eto;Diabetes Obes Metab,2012

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of teneligliptin in patients with type 2 diabetes mellitus: a Bayesian network meta-analysis;Frontiers in Endocrinology;2023-12-18

2. Physiology, pharmacology and prospects for dipeptidilpeptidase-4 inhibitors use;Pharmacy & Pharmacology;2023-04-28

3. Prescription patterns and therapeutic effects of second-line drugs in Japanese patients with type 2 diabetes mellitus: Analysis of claims data for metformin and dipeptidyl peptidase-4 inhibitors as the first-line hypoglycemic agents;Expert Opinion on Pharmacotherapy;2023-04-26

4. Systematic review and meta-analysis of teneligliptin for treatment of type 2 diabetes;Journal of Endocrinological Investigation;2023-01-09

5. Comparison of efficacy between canagliflozin and teneligliptin as add-on therapy to metformin and glimepiride on plasma glucose levels along with blood pressure and lipid levels in patients with type 2 diabetes mellitus;Journal of Diabetology;2023